The molecular mechanism of arsenic trioxide-induced apoptosis and oncosis in leukemia/lymphoma cell lines

Acta Haematologica

Volumn 110, Issue 1, 2003, Pages 1-10

  Zhu, Jiebin ^a   Okumura, Hirokazu ^a   Ohtake, Shigeki ^b   Nakamura, Shinobu ^c   Nakao, Shinji ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Arsenic trioxide; Bcl 2; Caspase 3; Caspase 8; CD95 CD95L; Leukemia lymphoma; Oncosis

Indexed keywords

ARSENIC TRIOXIDE; CASPASE 3; CASPASE 8; CASPASE INHIBITOR; FAS ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CELL CYCLE G1 PHASE; CELL GROWTH; CELL KILLING; CHRONIC MYELOID LEUKEMIA; DOWN REGULATION; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOMA CELL; MOLECULAR MECHANICS; MORPHOLOGY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; UPREGULATION;

ACUTE DISEASE; AMINO ACID CHLOROMETHYL KETONES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CASPASE 3; CASPASE 8; CASPASE 9; CASPASES; CELL DIVISION; CYSTEINE PROTEINASE INHIBITORS; DOWN-REGULATION; FAS LIGAND PROTEIN; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOID; MEMBRANE GLYCOPROTEINS; OXIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0141453490     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072407     Document Type: Article

References (30)

1. Majno G, Joris I: Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 1995;146:3-15.
2. Fisher DE: Cell. Apoptosis in cancer therapy: Crossing the threshold. Cell 1994;78:539-542.
3. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996;88:1052-1061.
4. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-3360.
5. Konig A, Wrazel L, Warrell RP Jr, Rivi R, Pandolfi PP, Jakubowski A, Gabrilove JL: Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 1997;90:562-570.
6. Li YM, Broome JD: Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 1999;59:776-780.
7. Ishitsuka K, Hanada S, Suzuki S, Utsunomiya A, Chyuman Y, Takeuchi S, Takeshita T, Shimotakahara S, Uozumi K, Makino T, Arima T: Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. Br J Haematol 1998;103:721-728.
8. Lu M, Levin J, Sulpice E, Sequeira-Le Grand A, Alemany M, Caen JP, Han ZC: Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. Exp Hematol 1999;27:845-852.
9. Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MH, Brouet JC, Fermand JP: Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 1999;59:1041-1048.
10. Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Nakamura S, Takeshita K, Takeshita A, Ohno R: The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998;12:1383-1391.
11. Akao Y, Nakagawa Y, Akiyama K: Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 1999;455:59-62.
12. Wang ZG, Rivi R, Delva L, Konig A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, Warrell RP Jr, Pandolfi PP: Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner. Blood 1998;92:1497-1504.
13. Dai J, Weinberg RS, Waxman S, Jing Y: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999;93:268-277.
14. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, Kim BK, Lee YY: Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000;60:3065-3071.
15. Kitamura K, Minami Y, Yamamoto K, Akao Y, Kiyoi H, Saito H, Naoe T: Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 2000;14:1743-1750.
16. Seol JG, Park WH, Kim ES, Jung CW, Hyun JM, Lee YY, Kim BK: Potential role of caspase-3 and -9 in arsenic trioxide-mediated apoptosis in PCI-1 head and neck cancer cells. Int J Oncol 2001;18:249-255.
17. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
18. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-279.
19. Aiello A, Delia D, Borrello MG, Biassoni D, Giardini R, Fontanella E, Pezzella F, Pulford K, Pierotti M, Della Porta G: Flow cytometric detection of the mitochondrial BCL-2 protein in normal and neoplastic human lymphoid cells. Cytometry 1992;13:502-509.
20. Ashkenazi A, Dixit VM: Death receptors: Signaling and modulation. Science 1998;281:1305-1308.
21. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817-827.
22. Boldin MP, Goncharov TM, Goltsev YV, Wallach D: Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996;85:803-815.
23. Fulda S, Scaffidi C, Pietsch T, Krammer PH, Peter ME, Debatin KM: Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma-irradiation-induced apoptosis of brain tumor cells. Cell Death Differ 1998;5:884-893.
24. Fulda S, Los M, Friesen C, Debatin KM: Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer 1998;76:105-114.
25. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM: The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997;57:3823-3829.
26. Nakamura S, Takeshima M, Nakamura Y, Ohtake S, Matsuda T: Induction of apoptosis in HL60 leukemic cells by anticancer drugs in combination with anti-Fas monoclonal antibody. Anticancer Res 1997;17:173-179.
27. Friesen C, Herr I, Krammer PH, Debatin KM: Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996;2:574-577.
28. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S: Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999;94:2102-2111.
29. Chen YC, Lin-Shiau SY, Lin JK: Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol 1998;177:324-333.
30. McCabe MJ Jr, Singh KP, Reddy SA, Chelladurai B, Pounds JG, Reiners JJ Jr, States JC: Sensitivity of myelomonocytic leukemia cells to arsenite-induced cell cycle disruption, apoptosis, and enhanced differentiation is dependent on the inter-relationship between arsenic concentration, duration of treatment, and cell cycle phase. J Pharmacol Exp Ther 2000;295:724-733.